Markets
General Views In New York
A Bald Eagle flies over Caroons Lake (Photo by Bruce Bennett/Getty Images)

Keep an eye on the tumbling US dollar

The dollar has slumped against the yen, and is reaching a critical inflection point versus other major currencies as well.

Luke Kawa

The eagle’s wings have been clipped.

The US dollar is sinking like a stone, with the Bloomberg Dollar Spot Index down 1% over the past three sessions and more than 3% off its late June 2024 peak.

Of course, the biggest factor behind the ferocity of the USD decline in August was the unwind of the yen carry trade, which propelled the Japanese currency sharply higher.

Analysts at Bespoke Investment Group note that, through Monday, “2.0 percentage points of [the Bloomberg Spot Index’s] total drop has come from the yen, which has gained almost 10 percentage points against the dollar during its recent short squeeze.”

“All other currencies have accounted for only slightly more than 1% of the drop,” they add. “This USD decline is far less about broad dollar weakness than the yen story,”

USD Decline
Bespoke Investment Group

But scan across the foreign exchange universe, and we’re reaching the point where this could transform from “yen strength” to “broad dollar weakness” – or this nascent trend could peter out. 

A suite of central bank speeches at the Jackson Hole Economic Symposium this week – chiefly, Fed Chair Jerome Powell’s address on Friday, could be major currency catalysts.

An overarching reason for the greenback’s swoon has been a narrowing of interest rate differentials between the US and other major economies as expectations for Federal Reserve easing have ratcheted higher. This reduces the appeal of holding the US dollar because you’re getting less extra income from investing in short-term, safe US debt obligations compared to other nations.

Traders are currently pricing about 75% odds that the US central bank delivers a 25 basis point rate cut at its September meeting, and 25% odds of a 50 basis point reduction.

It’s highly unlikely that Powell telegraphs a big cut this week, with another round of jobs data as well as PCE and CPI inflation reports on tap before the next decision.

Other crosses have also moved quite a bit since the US dollar’s 2024 peak; the Swiss franc, South Korean won, and euro are all up more than 4% versus the greenback. The euro is far and away the biggest component of the Bloomberg Dollar Spot Index.

“The euro is right at a huge level as we have closed above 1.1100 just nine times in the past two years,” writes Brent Donnelly, president of Spectra Markets. “We have only closed above 1.1130 five times in the last two years. We are in rarified air.”

EURUSD distribution
Spectra Markets

Not only the euro, but the currency of America’s neighbor to the north is also at an inflection point. USDCAD is closing in on 1.36, a key level where previous rallies in the Canadian dollar have fizzled out so far this year.

Donnelly flagged two made-in-Canada challenges for the currency in the near term. First, Alimentation Couche-Tard (translation: Late Night Snack) – the biggest retailer in Canada – made a bid to acquire Japanese company Seven & I Holdings (which operates 7-Eleven). Moving forward with that transaction could involve selling a lot of Canadian dollars to buy Japanese yen. Secondly, the looming rail strike in Canada would be a negative for the domestic economy in addition to disrupting North American trade.

For these reasons, he says  “I would definitely not be long CAD right now (against anything)” over the next few weeks with these idiosyncratic negatives percolating in the background.

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets
Luke Kawa

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.